Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Dose Escalation Study With A Double Blind Randomised Placebo Controlled Withdrawal To Examine The Effects Of The Histamine H3 Antagonist GSK189254 In Patients With Narcolepsy.

NCT00366080 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00366080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00366080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Dose Escalation Study With A Double Blind Randomised Placebo Controlled Withdrawal To Examine The Effects Of The Histamine H3 Antagonist GSK189254 In Patients With Narcolepsy.
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2006
Completion date
January 31, 2008
Enrollment
69 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

narcolepsy